MediPharm Labs: Two Quarters of Profit, a $19 Million Market Cap, and a $15 Million Appraisal Nobody's Pricing
The Canadian cannabinoid processor posted its second straight positive net income and third straight positive adjusted EBITDA — but the call was answered only by webcast questions, and the U.S. rescheduling catalyst that once anchored the bull case has quietly vanished from the script
LABS.TO · Earnings Call · 2026-11-12
A micro-cap that finally stopped leaking
MediPharm Labs reported Q3 2026 on 2026-11-12 with net revenue of $11.8 million, up 18% sequentially, gross profit of $3.8 million (32% margin, up 27% year-over-year), and operating expenses down 25% year-over-year to $3.6 million. Adjusted EBITDA was positive $0.4 million — the third consecutive quarter of positive adjusted EBITDA — and net income was positive for a second straight quarter. For a company whose market capitalization sits near $19.5 million, that is not a rounding error; it is the first genuine inflection in years.
“We delivered 1 of our strongest revenue quarters in recent years, achieved positive net income for the second consecutive quarter and delivered our third consecutive positive adjusted EBITDA.” — Greg Hunter, CEO and CFO · 2026-11-12
The company's own keyword trail this quarter reads like a management team that knows it has to prove durability rather than ambition: medical market, financial discipline, manufacturing capability, sustainable margin. Those are the words of a business arguing for its right to exist, not one selling a dream. Notably, "pricing pressure" (pricing pressure) climbed to its highest salience yet — because the growth is coming from markets where price is under attack.
Germany carries it; Australia is being recalibrated, not fixed
International medical revenue was $6.9 million, roughly 59% of the total, up 20% sequentially. Germany hit $5 million (+19% qoq, +81% yoy) on flower, oil and dronabinol, while the U.K. grew 220%. Canada medical held flat at $2.3 million, adult-use/wellness slipped to $1.4 million from $1.5 million, and pharma/B2B rose to $1.2 million.
The honest part of the call was Australia. It was not spun as a temporary blip.
The market is going through what I would characterize as a period of normalization following increased regulatory scrutiny and enforcement actions that have contributed to lower overall market volumes... we view this more as a market recalibration rather than a fundamental underlying change in patient demand.
That language — regulatory scrutiny plus pricing pressure plus channel inventory reductions — is the same diagnosis Greg Hunter gave in August, when he noted regulators "starting to take a closer look at the market." What's changed is the remedy: MediPharm refreshed its Beacon and Wildlife branded portfolios and pushed Wildlife into the value segment. That is a defensive move into the price war, not an escape from it. The strategic irony is that MediPharm's EU-GMP stack — the thing it sells as its moat — does not protect flower pricing when the market tilts to value.
The things management stopped saying
The most interesting signal in this report is absence. Earlier this year, the U.S. rescheduling of cannabis to Schedule III (Schedule III) was the marquee question. In May, an Alliance Global analyst pressed it directly:
“When we think about the U.S. and Phase I, call it, rescheduling... is this the big catalyst for you to be able to now execute on the strategy vis-a-vis APIs and research in the U.S.?” — Aaron Grey, Analyst · 2026-05-13
Hunter's answer then was already deflationary — "this isn't a short-term immediate impact to the P&L in the next quarter." By the Q3 call, Schedule III has evaporated entirely. The U.S. now appears only as a footnote about shipping trial material "under a strict regulatory framework." The company's keyword set has stopped surfacing it. That is a catalyst being quietly retired, not refuted.
Equally telling: this call's Q&A consisted of three operator-read webcast questions — Brazil, Australia, and the LiBBY trial. No live sell-side analyst asked anything. In May, Aaron Grey of Alliance Global Partners was on the line asking two questions. The sell-side has left the building. Management's LiBBY commentary — Phase II efficacy in advanced dementia agitation, presented at the Alzheimer's Association International Conference in July, two U.S. provisional patents filed, "next steps... additional clinical development or regulatory pathways and/or strategic partnerships" — is now a third consecutive quarter of the same update with no new milestone. Continuity disguised as progress.
Geography shows the same fade. Metered dose inhalers and Brazil got fresh news (a first CBD oral oil launch with Alko do Brasil through national pharmacy channels; a first inhaler shipment into Panama post-quarter). But France and New Zealand — heavily promoted in prior calls — drew no authorization update and have dropped off the company's own keyword salience entirely this quarter.
The valuation oddity that management keeps repeating
Hunter leaned, again, on a line he has used for roughly two years: more than $10 million of cash, "“virtually no debt and own 2 GMP production facilities with a combined appraised value in excess of $15 million” — Greg Hunter, CEO and CFO · 2026-11-12." The appraised value talking point has now appeared in the keyword record in at least four separate quarters. Management is making an explicit sum-of-the-parts argument to a market that is valuing the entire enterprise below cash-plus-property.
It is worth being clear-eyed about the other side. Adjusted EBITDA of $0.4 million on $11.8 million of revenue is a 3% margin; the trailing-twelve-month operating cash generation before working capital was about $1 million; and gross margin fell sequentially on product mix even as it rose year-over-year. The reimbursement changes from Veterans Affairs Canada — cutting the maximum reimbursable rate from $8.50 to $6.00 a gram, a 30% reduction effective April 1 — have now been fully absorbed but not reversed; Canadian medical revenue has simply stopped falling.
And on growth-by-acquisition, the language is deliberately unromantic: "“We do not view M&A as an objective in itself and are prepared to walk away when the economics do not meet our return thresholds.” — Greg Hunter, CEO and CFO · 2026-11-12" That sits alongside inorganic opportunities as a top-five theme — a company telling you it has a war chest, and simultaneously that it will not spend it. After the activist fight of 2025, that conservatism is probably the right answer; it is also why the equity has not re-rated.
The takeaway
MediPharm has crossed from existential to merely small. Two consecutive profitable quarters and three of positive adjusted EBITDA on a $19.5 million market cap, with $10 million of cash and no debt, is a legitimate setup — but the engine, International Medical via Germany and the U.K., is running into a value-price market, and the domestic medical channel is flat by design. With no analyst coverage attending the call and the Schedule III narrative shelved, the re-rating has to come from operating proof — another two or three quarters of this — or from management finally deploying the balance sheet. The commercial platform is real; the audience for it, for now, is not.